Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

MABC1126-100UG Anti-EGFRvIII mutation Antibody, clone L8A4

Anti-EGFRvIII mutation, clone L8A4, Cat. No. MABC1126, is a mouse monoclonal antibody that detects Epidermal Growth Factor Receptor variant III and has been tested for use in ELISA, Flow Cytometry, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Anti-EGFRvIII mutation Antibody, clone L8A4 MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Research Category: Apoptosis & Cancer Gene Symbol: EGFR, ERBB, ERBB1, HER1 UniProt Number: P00533
MABC1126-100UG
100 μg  
Purchase on Sigma-Aldrich

Přehled

Replacement Information

Tabulka spec. kláve

Species ReactivityKey ApplicationsHostFormatAntibody Type
HELISA, FC, ICC, IHC, IH(P), WBMPurifiedMonoclonal Antibody
Description
Catalogue NumberMABC1126-100UG
DescriptionAnti-EGFRvIII mutation Antibody, clone L8A4
Alternate Names
  • Epidermal Growth Factor Receptor vIII
Background InformationEpidermal growth factor receptor (UniProt: P00533; also known as EC:2.7.10.1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1) is encoded by the EGFR (also known as ERBB, ERBB1, HER1) gene (Gene ID: 1956) in human. EGFR is a single-pass type 1 membrane protein that is ubiquitously expressed. It is synthesized with a 24 amino acids signal peptide that is subsequently cleaved. It contains an extracellular domain (aa 25-645) a transmembrane domain (aa 646-668), and a cytoplasmic domain (aa 669-1210). Upon binding of EGF, the receptor is phosphorylated and recruits adapter proteins to turn on downstream signaling cascades. EGFR is commonly overexpressed and is mutated in many human malignancies and is often associated with aggressive phenotypes. The most common truncated EGFR is the variant III EGFR deletion mutant (EGFRvIII), containing an inframe deletion of exons 2 7 (801 bp) from the extracellular domain. EGFRvIII mutation is reported in about 5% of human lung squamous cell carcinoma (SCC). It has also been suggested that EGFRvIII potentially plays an essential role in the human NSCLC tumor initiation and maintenance. Drugs such as Gefitinib, erlotnib, and HKI-272 are shown to inhibit the growth of EGFRvIII transformed cells and tumor growth. This monoclonal antibody binds specifically to the epidermal growth factor receptor variant III (EGFRvIII), which is present on gliomas, but not normal tissues, and is internalized rapidly after receptor binding. (Ref.: Ji, H., et al. (2006). Proc. Natl. Acad. Sci. USA 103(20); 7817-7822; Hens, M., et al. (2010). Nucl. Med. Biol. 37(7); 741-750).
References
Product Information
FormatPurified
PresentationPurified mouse monoclonal antibody IgG1 in PBS without azide.
Applications
ApplicationAnti-EGFRvIII mutation, clone L8A4, Cat. No. MABC1126, is a mouse monoclonal antibody that detects Epidermal Growth Factor Receptor variant III and has been tested for use in ELISA, Flow Cytometry, Immunocytochemistry, Immunohistochemistry, Immunohistochemistry (Paraffin), and Western Blotting.
Key Applications
  • ELISA
  • Flow Cytometry
  • Immunocytochemistry
  • Immunohistochemistry
  • Immunohistochemistry (Paraffin)
  • Western Blotting
Application NotesWestern Blotting Analysis: A representative lot detected EGFRvIII mutation in Western Blotting applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Grandi, P., et. al. (2010). Cancer Gene Ther. 17(9):655-63; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

Immunohistochemistry (Paraffin) Analysis: A representative lot detected EGFRvIII mutation in Immunohistochemistry applications (Mellinghoff, I.K., et. al. (2005). N Engl J Med. 353(19):2012-24; Sok, J.C., et. al. (2006). Clin Cancer Res. 12(17):5064-73).

Immunohistochemistry Analysis: A representative lot detected EGFRvIII mutation in Immunohistochemistry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

ELISA Analysis: A representative lot detected EGFRvIII mutation in ELISA applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

Flow Cytometry Analysis: A representative lot detected EGFRvIII mutation in Flow Cytometry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Wikstrand, C.J., et. al. (1995). Cancer Res. 55(14):3140-8).

Immunocytochemistry Analysis: A representative lot detected EGFRvIII mutation in Immunocytochemistry applications (Wikstrand, C.J., et. al. (1998). J Neuroviral. 4(2):148-58; Batra, S.K., et. al. (1995). Cell Growth Differ. 6(10):1251-9).
Biological Information
ImmunogenKLH-conjugated linear peptide corresponding to the predicted amino acid sequence of 14 amino acids at the fusion junction combined with cultured HC2 20 d2 cells.
CloneL8A4
ConcentrationPlease refer to lot specific datasheet.
HostMouse
SpecificityClone L8A4 specifically binds to EGFRvIII, a mutated form of EGFR.
IsotypeIgG1κ
Species Reactivity
  • Human
Species Reactivity NoteHuman.
Antibody TypeMonoclonal Antibody
Entrez Gene Number
Gene Symbol
  • EGFR
  • ERBB
  • ERBB1
  • HER1
Purification MethodProtein G purified
UniProt Number
Molecular Weight~145 kDa observed. Uncharacterized bands may be observed in some lysate(s).
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceEvaluated by Western Blotting in NR6 cells expressing human EGFRvIII (NR6M).

Western Blotting Analysis: 1 µg/mL of this antibody detected EGFRvIII mutation in NR6 cells expressing human EGFRvIII (NR6M).
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at -20°C from date of receipt.

Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Packaging Information
Material Size100 μg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
MABC1126-100UG 04054839507267

Documentation

Anti-EGFRvIII mutation Antibody, clone L8A4 MSDS

Title

Safety Data Sheet (SDS) 

Anti-EGFRvIII mutation Antibody, clone L8A4 Certificates of Analysis

TitleLot Number
Anti-EGFRvIII mutation, clone L8A4 - 3163451 3163451
Anti-EGFRvIII mutation, clone L8A4 - 3224552 3224552
Anti-EGFRvIII mutation, clone L8A4 - 3388986 3388986
Anti-EGFRvIII mutation, clone L8A4 - 3713361 3713361
Anti-EGFRvIII mutation, clone L8A4 - 3731578 3731578
Anti-EGFRvIII mutation, clone L8A4 - 3874285 3874285
Anti-EGFRvIII mutation, clone L8A4 - 3949762 3949762
Anti-EGFRvIII mutation, clone L8A4 - 4013366 4013366
Anti-EGFRvIII mutation, clone L8A4 - 4107271 4107271
Anti-EGFRvIII mutation, clone L8A4 Monoclonal Antibody Q3049674